Curcumin is used in the treatment of colon cancer, but its very poor absorption in the upper part of the GIT is a major concern. As a site for drug delivery, the colon offers a near neutral pH, reduced digestive enzymatic activity, a long transit time and an increased responsiveness to absorption enhancers. The aim of the present study was to identify a suitable polymer (guar gum) based matrix tablet for curcumin with sufficient mechanical strength and promising in vitro mouth-to-colon release profile. Three formulations of curcumin were prepared using varying concentrations of guar gum containing 50 mg curcumin by the wet granulation method. Tablets were subjected to evaluation by studying parameter like hardness, friability, drug content uniformity, and in-vitro drug release. In vitro drug release was evaluated using simulated stomach, intestinal and colonic fluids. The susceptibility of guar gum to colonic bacteria was also assessed by a drug release study with rat caecal contents. The 40% guar gum containing formulation (F-1) showed better drug release (91.1%) after 24 hours in the presence of rat caecal contents in comparison with the 50% guar gum containing formulation (F-2) (82.1%). Curcumin could, thus, be positively delivered to the colon for effective colon cancer treatment using guar gum.
In recent times, colon targeted drug delivery systems have gained importance for the systemic delivery of protein and peptide drugs [1] . Drug delivery to the colon is desired not only for oral delivery of peptide and proteins but also to treat different diseases associated with the colon, such as irritable bowel syndrome, colon cancer, colitis and ulcerative colon [2] . Drug targeting to the colon is also useful when a delay in drug absorption is desired from a therapeutic point of view, such as the treatment of diseases that have peak symptoms in the early morning, like nocturnal asthma, angina and arthritis [1] . By definition, an oral colonic delivery system should retard drug release in the stomach and small intestine, but allow complete release in the colon. The fact that such a system will be exposed to a diverse range of gastrointestinal conditions on passage through the gut makes colonic delivery via the oral route a challenging proposition. Targeted drug delivery to the colon would, therefore, ensure direct treatment at the disease site, lower dosing, and fewer systemic side effects [3] .
Curcumin is the principal curcuminoid of the popular Indian curry spice turmeric. The curcuminoids are polyphenols and are responsible for the yellow color of turmeric. Curcumin is known for its antitumor, antioxidant, antiarthritic, anti-amyloid, anti-ischemic and anti-inflammatory properties [4] . Its anticancer effects stem from its ability to induce apoptosis in cancer cells without cytotoxic effects on healthy cells. Curcumin can interfere with the activity of the transcription factor NF-κB, which has been linked to a number of inflammatory diseases, such as cancer. Indeed, when 0.2% curcumin was added to the diet of either rats or mice previously given a carcinogen, it significantly reduced colon carcinogenesis [5] .
The inability of GIT enzyme to digest certain plant polysaccharides can be used to advantage to develop colon specific drug delivery systems. A biodegradable polymer matrix is produced by compressing a blend of active drug, a biodegradable polymer and additives. Various polysaccharides have being evaluated for colon targeting like pectin, guar gum, gum ghatti, dextran, chitosan, and xylan. Guar gum, obtained from the ground endosperm of Cyamposis tetragonolobus, consists chiefly of high molecular weight hydrocolloidal polysaccharides composed of galactan and mannan units combined through glycosidic linkages. The gum undergoes degradation in the large intestine due to the presence of microbial enzymes. It contains about 80% galactomannan, 12% water, 5% protein, 2% acid soluble ash, and 0.7% fat. Guar gum has a molecular weight of approximately 1 million Daltons, giving it a high viscosity in solution. This galactomannan is soluble in cold water, hydrating quickly to produce viscous pseudoplastic solutions that generally have greater low-shear viscosity than other hydrocolloids. This gelling property retards release of the drug from the dosage form, and it is susceptible to degradation in the colonic environment. Guar gum is being extensively studied by many researchers for colon targeting. The bacterial enzymes of the colon degrade the carrier polymer in a well defined way and release the contents for localized colonic delivery or systemic absorption through the colon [6, 7] . In this regard, our aim was directed at identifying guar gum as a polymer suitable for the delivery of curcumin in the colon.
The characters of the guar gum used are reported in Table 1 . This gum was used to prepare two formulations of curcumin ( Table 2 ). The characteristics of the formulations are presented in Table 3 . Drug release studies were carried out using the USP dissolution rate test apparatus (Apparatus 1, 100 rpm, 37 o C) for 2 h in 0.1N HCl (900 mL).
To enhance the solubility of curcumin, 2% SLS was added to the formulations, and matrix tablets were prepared. F-1 and F-2 gave 68.7 and 55.7 cumulative percentage drug release without rat caecal content. In the in-vitro drug release study, when the curcumin tablet was formulated without guar gum (F-3), 63.2% drug release was observed after 5 hours (up to small intestine). However, when formulated with guar gum, only 3.1% and 2.4% drug release (for 40% and 50% guar gum containing formulations, respectively) was observed in the upper part of the gastrointestinal tract (g. i. t.), which indicates the capability of guar gum to protect the active medicaments from release in the upper part of g. i. t. The 40% guar gum containing formulation (F-1) showed better drug release (91.1% after 24 hours) in the presence of rat caecal contents in comparison with the 50% guar gum containing formulation (F-2), which released 82.1% ( Table 5 ). The results of cumulative percentage drug release of the different formulations with rat caecal contents are given in Table 5 . Guar gum is susceptible to enzymatic action of caecal contents that cause better drug release (91.1%, F-1) (82.1%, F-2) in the presence of rat caecal contents than in their absence.
Guar gum is a natural polymer that has been used frequently as a carrier in colon targeting. The gum contains highly branched galactomannans, cleavage of Colon targeted curcumin delivery Natural Product Communications Vol. 5 (6) 2010 917 which by either enzymatic or acid hydrolysis does not reduce viscosity to the same extent as cleavage of the more linear galactomannans. The highly branched molecular structure of guar gum resists enzymatic breakdown in the digestive tract. Also, in vitro evaluation of tablets prepared using guar gum showed that it is capable of protecting the drug from being released in the physiological environment of the stomach and small intestine [7] . The presence of rat caecal content in the dissolution medium resulted in improved drug release at different time periods when compared with the control. In-vitro evaluation demonstrated that guar gum is susceptible to enzymatic action of caecal contents that caused better drug release in the presence of rat caecal contents than without. Hence, guar gum may be used as a potential carrier for colon specific drug delivery.
The present study concludes that guar gum has the capability to protect the release of curcumin from the stomach and small intestine. By using this approach, curcumin could be used in the treatment of colon cancer and the oral dose could be decreased, but with the bioavailability increased.
Experimental
Chemicals: Guar gum and curcumin were purchased from National Chemical, Vadodara, Gujarat.
Identification and characterization of guar gum:
The guar gum was identified and characterized using features such as particle characters, angle of repose, bulk density, tape density, Hausner ratio, and loss on drying [8, 9] .
Curcumin tablet formulation using guar gum:
Matrix tablets using guar gum were prepared by wet granulation. Lactose was used as diluent and a mixture of talc-magnesium stearate (2:1) was employed as lubricant. Guar gum was included in the formulations in various proportions (Table 3 ). In all the formulations, guar gum was sieved (< 250 µm) separately and mixed with drug (< 150 µm) and lactose (< 250 µm). The powders were blended and granulated with 8% starch paste. The wet mass was passed through sieve no. 18 and the granules were dried at 50 o C for 2 h. The dried granules were passed through a no. 22 sieve and lubricated with a mixture of talc-magnesium stearate (2:1). The lubricated granules were added to an eight station tabletting machine for formulation of the matrix tablets. A separate formula (F-3) was used to prepare tablets without guar gum (control).
Evaluation of tablets:
Evaluation of tablets included parameters like weight variation, hardness, friability and content uniformity [10] .
In-vitro drug release studies in 0.1N HCL, pH 7.4 Sorensen's phosphate buffer, and pH 6.8 Sorensen's phosphate buffer: The ability of the matrix tablets of curcumin to remain intact in the physiological environment of the stomach and small intestine was assessed by conducting drug release studies under conditions mimicking mouth to colon transit. Drug release studies were carried out using the USP dissolution rate test apparatus (Apparatus 1, 100 rpm, 37 o C) for 2 h in 0.1N HCl (900 mL). Then the dissolution medium was replaced with pH 7.4 phosphate buffer (900 mL) and tested for drug release for 3 h. After that, the dissolution medium was replaced with pH 6.8 phosphate buffer (900 mL) and experiment was continued up to 24 h. At different time intervals, 5 mL of the sample was withdrawn without pre-filtering and replaced with 5 mL of fresh phosphate buffer. One mL of the liquid was suitably diluted, filtered and analyzed for percentage drug release at 421 nm for curcumin by an UV method using a double beam UVspectrophotometer. The % drug release was calculated using the standard curve of curcumin in different dissolution media [1, [11] [12] [13] .
Drug release in the presence of rat caecal contents:
To assess the susceptibility of guar gum being acted upon by colonic bacteria, drug release studies were carried out in the presence of rat caecal contents because of their similarity to human intestinal microflora. In order to induce enzymes that specifically act on guar gum in the caecum, male albino rats maintained on normal diet were administered with 4 mL of a 1% dispersion of guar gum in water for 7 days. Thirty mins before the commencement of drug release studies, 3 rats were killed by spinal traction. The abdomen was opened, isolated, ligated at both ends, cut loose and transferred into pH 6.8 phosphate buffer, previously bubbled with CO 2 . The rat caecal bags were opened, their contents weighed and 4% w/v solution of rat caecal contents was prepared in 6.8 phosphate buffer.
